<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05070455</url>
  </required_header>
  <id_info>
    <org_study_id>ADMA-004</org_study_id>
    <nct_id>NCT05070455</nct_id>
  </id_info>
  <brief_title>An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)</brief_title>
  <official_title>An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ADMA Biologics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ADMA Biologics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IV, multicenter, open-label study of Asceniv™ administered as an intravenous&#xD;
      infusion of Asceniv™ (IGIV) 300-800 mg/kg every 21 or 28 days in approximately 12 pediatric&#xD;
      subjects with Primary Immunodeficiency Diseases (PIDD). The study will be conducted at 5-7&#xD;
      centers in the United States, with subjects receiving six (28 day cycle) or seven (21 day&#xD;
      cycle) doses of Asceniv™ during the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>At prior to, end of infusion, and 60 minutes, 2 hours, 24 hours, 48 hours, 4 days, 7 days, 14 days, and either 21 or 28 days dependent upon infusion schedule</time_frame>
    <description>Pharmacokinetic measure at 6th or 7th infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>At prior to, end of infusion, and 60 minutes, 2 hours, 24 hours, 48 hours, 4 days, 7 days, 14 days, and either 21 or 28 days dependent upon infusion schedule</time_frame>
    <description>Pharmacokinetic measure at 6th or 7th infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-ʈ)</measure>
    <time_frame>At prior to, end of infusion, and 60 minutes, 2 hours, 24 hours, 48 hours, 4 days, 7 days, 14 days, and either 21 or 28 days dependent upon infusion schedule</time_frame>
    <description>Pharmacokinetic measure at 6th or 7th infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-∞)</measure>
    <time_frame>At prior to, end of infusion, and 60 minutes, 2 hours, 24 hours, 48 hours, 4 days, 7 days, 14 days, and either 21 or 28 days dependent upon infusion schedule</time_frame>
    <description>Pharmacokinetic measure at 6th or 7th infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal phase elimination half-life (ʈ½)</measure>
    <time_frame>At prior to, end of infusion, and 60 minutes, 2 hours, 24 hours, 48 hours, 4 days, 7 days, 14 days, and either 21 or 28 days dependent upon infusion schedule</time_frame>
    <description>Pharmacokinetic measure at 6th or 7th infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal phase elimination rate (λZ)</measure>
    <time_frame>At prior to, end of infusion, and 60 minutes, 2 hours, 24 hours, 48 hours, 4 days, 7 days, 14 days, and either 21 or 28 days dependent upon infusion schedule</time_frame>
    <description>Pharmacokinetic measure at 6th or 7th infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total IgG Trough</measure>
    <time_frame>At each visit through study completion, up to approximately 7 months</time_frame>
    <description>Levels taken before each infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG Subclasses</measure>
    <time_frame>Prior to first and last infusions</time_frame>
    <description>Levels of subclasses 1-4 before infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibodies</measure>
    <time_frame>Prior to first and last infusions</time_frame>
    <description>Levels of specific antibodies (anti-pneumococcal capsular polysaccharide, anti-haemophilus influenzae b, and anti-RSV neutralizing antibody)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>Up to approximately 7 months</time_frame>
    <description>Number of infections of any kind, serious and non-serious</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Bacterial Infections</measure>
    <time_frame>Up to approximately 7 months</time_frame>
    <description>Incidence of Serious Bacterial Infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Infections</measure>
    <time_frame>Up to approximately 7 months</time_frame>
    <description>Incidence of infections other than Serious Bacterial Infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>Up to approximately 7 months</time_frame>
    <description>Number of hospitalizations due to infections</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Primary Immune Deficiency</condition>
  <arm_group>
    <arm_group_label>Asceniv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asceniv™ will be given as an intravenous infusion at the same dose, or higher dose where medically appropriate, as the subject's previous IV Immunoglobulin G treatment (300-800 mg/kg) every 21 or 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Asceniv™</intervention_name>
    <description>Each subject will receive an intravenous infusion of Asceniv™ on Study Day 1 (required to be within 28 days of screening) and every 21 or 28 days thereafter according to their current interval of IGIV treatment. Subjects will receive Asceniv™ at the same dose or higher dose if medically appropriate (300-800 mg/kg), every 21 or 28 days for five months (seven or six doses respectively).</description>
    <arm_group_label>Asceniv</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject and/or legal guardian must be able to understand the study procedures, have&#xD;
             agreed to participate in the study and have voluntarily signed an IEC/IRB approved&#xD;
             written informed consent. The consent form or a specific assent form, where required,&#xD;
             will be signed and dated by minors.&#xD;
&#xD;
          2. Have confirmed and documented clinical diagnosis of primary immunodeficiency disease&#xD;
             including but not limited to: common variable immunodeficiency, X-linked and autosomal&#xD;
             forms of agammaglobulinemia, hyper-IgM syndrome, or antibody deficiencies.&#xD;
&#xD;
          3. Be male or female, and ≥ 2 years and &lt; 12 years at the time of informed consent by&#xD;
             subject or legal guardian.&#xD;
&#xD;
          4. Have been receiving IGIV at a dose that has not been changed by &gt; 25% of the mean dose&#xD;
             on a mg/kg basis for at least 3 months prior to study entry.&#xD;
&#xD;
          5. Have two trough levels of IgG in the last year (screening level may be used), and&#xD;
             maintained a trough serum IgG level &gt; 500 mg/dL on the previous 2 assessments prior to&#xD;
             receiving Asceniv™. (The trough level must be at least 300 mg/dL above pre-treatment&#xD;
             serum IgG levels; with exception for cases of X-linked agammaglobulinemia where no&#xD;
             pre-treatment value is available. Documentation will need to include dose, treatment&#xD;
             interval and trade name of the IGIV products used for the three doses prior to the&#xD;
             first Asceniv™ infusion in this study.&#xD;
&#xD;
          6. For female subjects, be of non-childbearing potential or have a negative pregnancy&#xD;
             test prior to study start and be deemed not at risk of becoming pregnant by adherence&#xD;
             to a reliable contraceptive method for the duration of the study. Females of&#xD;
             non-childbearing potential are defined as prepubertal girls.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a known hypersensitivity to immunoglobulin or any excipient in Asceniv™.&#xD;
&#xD;
          2. Have a history of any severe anaphylactic or anaphylactoid reaction to blood or any&#xD;
             blood-derived product.&#xD;
&#xD;
          3. Have a specific Immunoglobulin A (IgA) deficiency (IgA ≤ 5 mg/dL and normal IgG and&#xD;
             IgM), history of allergic reaction to products containing IgA or has demonstrable&#xD;
             antibodies to IgA.&#xD;
&#xD;
          4. Have uncompensated, hemodynamically significant, congenital or other heart disease.&#xD;
             Including but not limited to acute coronary syndromes and chronic stable angina.&#xD;
&#xD;
          5. Have a medical condition that is known to cause secondary immune deficiency, such as&#xD;
             chronic lymphocytic leukemia, lymphoma, multiple myeloma, or HIV infection.&#xD;
&#xD;
          6. Have a significant T-cell or granulocyte deficiency in number or function (chronic or&#xD;
             recurrent absolute neutrophil count &lt;1000 x 109/L).&#xD;
&#xD;
          7. Have significant renal impairment (defined as an estimated Glomerular Filtration Rate&#xD;
             ≤ 50 mL/min/1.73m2); or have a history of acute renal failure.&#xD;
&#xD;
          8. Have abnormal liver function, defined as ALT or AST ≥ 2.5 x ULN.&#xD;
&#xD;
          9. Have any chronic lung disease (uncontrolled or chronic, severe asthma, etc.)&#xD;
&#xD;
         10. Have an infusion port, catheter, or other foreign body present (excluding PE tubes).&#xD;
             Long-standing, infection-free ports may be permitted at the discretion of the Medical&#xD;
             Monitor.&#xD;
&#xD;
         11. Be planned or scheduled to undergo surgery during the course of study participation.&#xD;
&#xD;
         12. Have ongoing failure to thrive per PI assessment.&#xD;
&#xD;
         13. Be receiving chronic anti-coagulation therapy.&#xD;
&#xD;
         14. Have a history of DVT, thrombotic or thrombo-embolic event, or are at increased risk&#xD;
             for thrombotic event due to presence of, but not limited to, atrial fibrillation,&#xD;
             disease or injury requiring prolonged immobilization, or other risk factor(s)&#xD;
             including significant proteinuria or protein losing enteropathy.&#xD;
&#xD;
         15. Current daily use of the following medications:&#xD;
&#xD;
               -  corticosteroids (&gt; 0.15 mg/kg/day of prednisone equivalent) Note: Intermittent&#xD;
                  corticosteroid use during the study is allowable, if medically necessary and&#xD;
                  approved by the ADMA Medical Director: i.e. 1 mg/kg twice a day for ten days to a&#xD;
                  maximum of 40 mg per dose&#xD;
&#xD;
               -  immunomodulatory drugs (e.g. TNF (inhibitors -Enbrel, Humira, etc.) Xolair and&#xD;
                  Dupixent administration permitted.&#xD;
&#xD;
               -  immunosuppressive drugs (excluding topical pimecrolimus (Elidel) and tacrolimus&#xD;
                  (Protopic))&#xD;
&#xD;
         16. Administration of a hyperimmune or specialty high titer Immunoglobulin product (e.g.&#xD;
             Cytogam, VZIG, HBIG, etc.) within 30 days of screening, or expectation that a&#xD;
             hyperimmune Immunoglobulin product will be given during the course of the study.&#xD;
&#xD;
         17. Have uncontrollable arterial hypertension.&#xD;
&#xD;
         18. Have anemia at screening (hemoglobin &lt;10 g/dL).&#xD;
&#xD;
         19. Have a history of hemolysis while undergoing treatment with IGIV therapy.&#xD;
&#xD;
         20. Be morbidly obese as indicated by a Body Mass Index (BMI) ≥40.&#xD;
&#xD;
         21. Have an active viral or bacterial infection or symptoms/signs consistent with such an&#xD;
             infection, within the two weeks prior to the Screening Visit. Subjects may be&#xD;
             receiving antibiotics as long as signs/symptoms of infection have been absent for two&#xD;
             weeks prior to the initial infusion of investigational product (IP).&#xD;
&#xD;
         22. Have received any blood product (other than Immunoglobulin G) within 3 months prior to&#xD;
             screening.&#xD;
&#xD;
         23. Have received any RSV specific products, including palivizumab (Synagis®) within 3&#xD;
             months prior to screening.&#xD;
&#xD;
         24. Have abused alcohol, opiates, psychotropic agents, or other chemicals or drugs within&#xD;
             the past 12 months.&#xD;
&#xD;
         25. Have an acute or chronic medical condition that, in the opinion of the investigator,&#xD;
             may interfere with the conduct of the study.&#xD;
&#xD;
         26. Have any condition judged by the study physician to preclude participation in the&#xD;
             study, including any psychological disorder, which might hinder compliance.&#xD;
&#xD;
         27. Have any laboratory assessment result that, in the opinion of the investigator,&#xD;
             warrants exclusion from participation in the study.&#xD;
&#xD;
         28. Are currently pregnant or nursing.&#xD;
&#xD;
         29. Have acute hepatitis A, acute or chronic Hepatitis B or C, or HIV infection.&#xD;
&#xD;
         30. Have received investigational product within 3 weeks of the anticipated first infusion&#xD;
             of Asceniv™.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rebecca Avila</last_name>
    <phone>561-989-5853</phone>
    <email>reavila@admabio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Doman</last_name>
    <email>adoman@admabio.com</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

